GoodRx (NASDAQ:GDRX) Given New $4.50 Price Target at Citigroup

GoodRx (NASDAQ:GDRX) had its target price reduced by Citigroup from $5.00 to $4.50 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also recently weighed in on GDRX. Weiss Ratings reiterated a “sell (d)” rating on shares of GoodRx in a research report on Tuesday, December 23rd. Morgan Stanley cut their price target on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. Mizuho lowered their price objective on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Barclays started coverage on GoodRx in a research report on Monday, December 8th. They set an “underweight” rating and a $3.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their target price on GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Five investment analysts have rated the stock with a Buy rating, five have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $4.91.

GoodRx Trading Up 0.4%

Shares of GDRX stock opened at $2.80 on Friday. GoodRx has a 1-year low of $2.61 and a 1-year high of $5.81. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock has a market cap of $950.40 million, a price-to-earnings ratio of 31.11, a PEG ratio of 1.04 and a beta of 1.45. The stock has a 50-day moving average of $2.84 and a 200-day moving average of $3.82.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $196.03 million during the quarter, compared to the consensus estimate of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business’s revenue was up .4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 earnings per share. On average, equities research analysts forecast that GoodRx will post 0.13 earnings per share for the current year.

Insider Buying and Selling at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total value of $95,084.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.53% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Quarry LP bought a new position in shares of GoodRx in the third quarter valued at $33,000. Cetera Investment Advisers bought a new position in GoodRx in the 2nd quarter valued at about $50,000. Boothbay Fund Management LLC acquired a new position in GoodRx during the 3rd quarter valued at about $43,000. Shay Capital LLC bought a new stake in GoodRx during the 3rd quarter worth approximately $47,000. Finally, Walled Lake Planning & Wealth Management LLC purchased a new stake in shares of GoodRx in the second quarter worth approximately $55,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.